Production (Stage)
Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.31M | 2.38M | 4.46M | 4.50M | 8.91M |
| Total Other Revenue | 1.84M | 1.89M | 2.18M | 2.20M | 2.63M |
| Total Revenue | 4.14M | 4.27M | 6.64M | 6.70M | 11.54M |
| Cost of Revenue | 12.21M | 12.59M | 15.65M | 15.78M | 13.23M |
| Gross Profit | -8.06M | -8.32M | -9.00M | -9.08M | -1.68M |
| SG&A Expenses | 5.40M | 5.57M | 5.16M | 5.20M | 4.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.61M | 18.16M | 20.80M | 20.98M | 18.15M |
| Operating Income | -13.46M | -13.89M | -14.16M | -14.28M | -6.60M |
| Income Before Tax | -13.17M | -13.58M | -13.33M | -13.44M | -5.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.17M | -13.58M | -13.33M | -13.44M | -5.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.17M | -13.58M | -13.33M | -13.44M | -5.00M |
| EBIT | -13.46M | -13.89M | -14.16M | -14.28M | -6.60M |
| EBITDA | -13.17M | -13.58M | -13.76M | -13.88M | -6.11M |
| EPS Basic | -0.16 | -0.17 | -0.16 | -0.17 | -0.06 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.10 | -0.10 | -0.04 |
| EPS Diluted | -0.16 | -0.17 | -0.17 | -0.17 | -0.06 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.10 | -0.10 | -0.04 |
| Average Basic Shares Outstanding | 81.23M | 81.23M | 80.87M | 80.87M | 80.59M |
| Average Diluted Shares Outstanding | 81.23M | 81.23M | 80.87M | 80.87M | 80.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |